Meng Xing, Zhang Kai, Zeng Wan-Jie, Hu Zhen-Hua
Clinical Laboratory, Suzhou Kowloon Hospital Affiliated with Shanghai Jiaotong University School of Medicine, Suzhou, Jiangsu, China.
Br J Hosp Med (Lond). 2024 Dec 30;85(12):1-13. doi: 10.12968/hmed.2024.0465. Epub 2024 Dec 9.
Chronic heart failure (CHF) is a complex clinical syndrome resulting from various cardiac diseases, characterized by weakened cardiac pumping capacity and inadequate blood supply to body tissues. This study aims to investigate the expression and clinical implications of pro-B-type natriuretic peptide (pro-BNP) and soluble suppression of tumorigenicity 2 (sST2) in CHF to explore their potential in early diagnosis and severity assessment of the pathological condition. This study included 146 CHF patients treated at our hospital from January 2022 to December 2023, who were classified in the observation group, and 150 concurrent healthy people categorized in the control group. pro-BNP and sST2 levels in the observation and control groups were compared. The diagnostic value of pro-BNP and sST2 in CHF was determined using receiver operating characteristic (ROC) curves. Besides, pro-BNP and sST2 levels in patients with different New York Heart Association (NYHA) grades were compared, and their relationships with left ventricular ejection fraction (LVEF), left atrial diameter (LAD), and left ventricular end-diastolic diameter (LVEDD) were assessed by means of Pearson's correlation. CHF cases showed markedly higher pro-BNP and sST2 levels than healthy controls ( < 0.05). The area under the ROC curves for pro-BNP and sST2 in diagnosing CHF was 0.826 (95% CI: 0.778-0.875) and 0.733 (95% CI: 0.674-0.791), respectively. pro-BNP and sST2 levels were similar in grades I and II patients ( > 0.05), but lower when compared with those in grades III and IV patients ( < 0.05). Grade III patients showed lower pro-BNP and sST2 expression than grade Ⅳ patients ( < 0.05). Additionally, pro-BNP and sST2 had an inverse connection with LVEF (r = -0.764 and r = -0.535, respectively) and a positive correlation with LAD (r = 0.752 and r = 0.535, respectively) and LVEDD (r = 0.721 and r = 0.544, respectively). pro-BNP and sST2 exhibit good diagnostic value for CHF, owing to their close association with patients' cardiac function. These biomarkers can be used as effective indicators to evaluate the severity of heart failure.
慢性心力衰竭（CHF）是一种由各种心脏疾病引起的复杂临床综合征，其特征是心脏泵血能力减弱，身体组织供血不足。本研究旨在探讨B型利钠肽原（pro-BNP）和可溶性肿瘤抑制因子2（sST2）在CHF中的表达及临床意义，以探索它们在早期诊断和病情严重程度评估方面的潜力。本研究纳入了2022年1月至2023年12月在我院接受治疗的146例CHF患者作为观察组，以及150例同期健康人作为对照组。比较观察组和对照组中pro-BNP和sST2水平。采用受试者工作特征（ROC）曲线确定pro-BNP和sST2对CHF的诊断价值。此外，比较不同纽约心脏协会（NYHA）分级患者的pro-BNP和sST2水平，并通过Pearson相关性分析评估它们与左心室射血分数（LVEF）、左心房内径（LAD）和左心室舒张末期内径（LVEDD）的关系。CHF患者的pro-BNP和sST2水平显著高于健康对照组（<0.05）。pro-BNP和sST2诊断CHF的ROC曲线下面积分别为0.826（95%CI：0.778-0.875）和0.733（95%CI：0.674-0.791）。I级和II级患者的pro-BNP和sST2水平相似（>0.05），但与III级和IV级患者相比更低（<0.05）。III级患者的pro-BNP和sST2表达低于IV级患者（<0.05）。此外，pro-BNP和sST2与LVEF呈负相关（r分别为-0.764和-0.535），与LAD呈正相关（r分别为0.752和0.535），与LVEDD呈正相关（r分别为0.721和0.544）。pro-BNP和sST2对CHF具有良好的诊断价值，因为它们与患者的心功能密切相关。这些生物标志物可作为评估心力衰竭严重程度的有效指标。
